Business
Cardio Diagnostics Holdings, Inc. Expands HeartRisk™ Platform Offering to Diverse Markets in Conjunction with Nationwide Rollout
Transformative Cardiovascular Risk Management Solutions Extend Beyond Traditional Sectors to Include Federal and State Correctional Facilities, Broker and
About this update from Cardio Diagnostics Holdings Inc.
[{"type":"text","content":"\nTransformative Cardiovascular Risk Management Solutions Extend Beyond Traditional Sectors to Include Federal and State Correctional Facilities, Broker and Benefits Organizations, and Risk Bearing Providers.\n\n\n CHICAGO--(BUSINESS WIRE)--\nCardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, announced today the nationwide rollout and a significant expansion of its groundbreaking HeartRisk™ platform. HeartRisk combines insights from HIPAA-compliant anonymized and aggregated clinical cardiovascular data obtained through Cardio Diagnostics’ Epi+Gen CHD and PrecisionCHD clinical tests, with industry and geographic data to enable real-time population-level cardiovascular disease (CVD) risk insights.\n\n\nThis expansion extends the reach of its proprietary data intelligence platform to correctional facilities, risk-bearing providers engaged in value-based contracts, and broker and benefits consultants. The move marks a strategic leap in addressing the financial and security challenges, such as those associated with transporting inmates in correctional facilities, of scaling access to cardiovascular testing across diverse sectors.\n\n\n\"By expanding our HeartRisk™ platform, we're not just innovating within traditional healthcare sectors but breaking new ground in diverse markets. From correctional facilities to value-based care providers and workplace wellness programs to brokerage and benefits consultants, our precision cardiovascular solutions provide actionable insights. By coupling data intelligence to evidence-based and scalable clinical tests, we're enabling these healthcare stakeholders and their organizations to make data-driven decisions to address rising healthcare costs and implement more effective chronic disease management. We're not just advancing precision medicine; we're ensuring those insights can be leveraged at the population level for multiple sectors,\" shared Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics.\n\n\nRisk-Bearing Providers and Value-Based Care\n\n\nRisk-bearing providers, such as Family Medicine Specialists that receive monthly HeartRisk population data, can better manage their shared-risk and value-based contracts by identifying and stratifying at-risk populations, and understanding the drivers of heart disease, ensuring quality me...